Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Majority of Patients with Serious Type of Bowel Disease Suffering Unnecessarily from Debilitating Symptoms


Print article Print article
© Business Wire 2014
2014-02-21 17:58:01 -

Patients with a serious type of inflammatory bowel disease, ulcerative colitis, are not satisfied with their current treatments and the majority do not have their disease under control, according to new research released today at the 9 th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen. The majority (87.2 per cent) of the 250 patients with moderate to severe ulcerative colitis who were being treated with standard therapies failed to achieve control of their disease – defined either as going into remission or not having needed to use corticosteroid medications in the previous two months. 1


The new findings from the Ulcerative Colitis Condition, Attitude, Resources and Educational Study (UC CARES) study across 11 European countries, including the United

Kingdom, showed that nearly half (46.8 percent) of patients reported not being satisfied with their current therapy for treating the painful and challenging symptoms of their ulcerative colitis. 1


Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD), that causes inflammation and ulceration in the inner lining of the large intestine (colon) or rectum (proctitis). 2 The most common symptoms of UC include abdominal pain and bloody diarrhoea. Patients also may experience fatigue, weight loss, loss of appetite and rectal bleeding. 2


Standard therapies, such as corticosteroids, aminosalicylates and thiopurines, are commonly prescribed for moderate-to-severe UC. However, the use of these therapies varies in clinical practice and it is unknown whether the disease is well controlled; few studies have comprehensively evaluated their effectiveness in disease control in real-world clinical practice. 1

UC CARES was designed to assess the level of unmet needs in disease control and treatment satisfactions among patients with moderate to severe UC receiving standard treatments such as corticosteroids, aminosalicylates (5-ASA), and thiopurine immunomodulators (AZA and 6-MP), but who were not previously treated with biologics. 1 These newer therapies work by blocking tumour necrosis factor (TNF)-alpha, a protein that when overproduced in the body plays a key role in the inflammation associated with the disease. 2 Currently, the National Institute for Health and Clinical Excellence (NICE) guidelines restrict use of biologic treatments to those patients who are at the acute severe end of the disease spectrum. 3


About ulcerative colitis

Around 146,000 people in the UK suffer from ulcerative colitis, 3 an autoimmune disease that causes the body to attack healthy tissue and leads to inflammation and ulceration of the large intestine and rectum. 2 Each year, between 6,000 and 12,000 people are diagnosed with the condition, 4 with the peak age of diagnosis between the ages of 15 and 25 years, followed by a smaller peak between 55 and 65 years. 3 When standard medications do not control the disease, surgery may be considered as an option to remove the affected colon (colectomy).

About one in four people with UC will require surgery at some time during their illness and it is estimated that around 20 per cent will undergo a colectomy within 10 years of diagnosis. 5,6


- Ends –


Notes to Editors:



About the UC CARES study 1


UC CARES is an observational, multicentre cross-sectional study designed to identify treatment satisfaction among patients with moderate-to-severe, active ulcerative colitis, and to assess knowledge and awareness of patients with regards to UC management. Study subjects included consecutive sample of patients aged 18 years or older, diagnosed with moderate-to-severe, active UC, naïve to biologic therapy who had received thiopurines, 5-ASA or corticosteroids during the 12 months prior to the study. Data were collected from questionnaire surveys of participating patients, in addition to review of medical charts in the past 12 months. Patients were enrolled from a total of 46 study sites from 11 European countries, including Belgium, France, Germany, Greece, Italy, The Netherlands, Spain, Sweden, Switzerland, Turkey and the United Kingdom. At the enrolment date, 63.2 percent were treated with thiopurines, 75.2 percent were treated with aminosalicylates, 23.6 percent were on corticosteroids, and 3.6 percent were treated with other types of immunosuppressants. A total of 250 patients were included in the final analysis. Data were collected from patient questionnaires at the date of enrolment and medical charts. 1

The study was commissioned by MSD in collaboration with IMS Health, a contract research organisation based in Barcelona, Spain. 1


About MSD

We believe the most important thing we make is a difference. We operate in more than 140 countries and through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products we work with customers to bring innovative healthcare solutions to those who need them the most. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programmes and partnerships. For more information visit www.msd-uk.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
MSD is a trade name of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.



References

1. ECCO 2014. Poster presentation. Van Assche, G., et. al., Disease Control and Unmet Needs Among Moderate to Severe Ulcerative Colitis Patients Treated with Conventional Therapies in Europe: The UC Cares (Ulcerative Colitis Condition, Attitude, Resources and Educational Study) Study. 2014


2. Crohn’s and Colitis UK. Ulcerative Colitis. Available at: www.nacc.org.uk/downloads/booklets/UlcerativeColitis.pdf : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
Accessed 6 February 2014.

3. National Institute for Health and Care Excellence. Ulcerative colitis: Management in adults, children and young people. June 2013.

Available at: publications.nice.org.uk/ulcerative-colitis-cg166 : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fpub .. .
Last accessed 12 February 2014.

4. Crohn’s and Colitis UK. Parents Need To Talk! Available at: www.crohnsandcolitis.org.uk/Resources/CrohnsAndColitisUK/Documen .. : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
Last accessed 12 February 2014.

5. Crohn’s and Colitis UK. Surgery for Ulcerative Colitis (UC).

Available at: www.nacc.org.uk/downloads/factsheets/SurgeryForUC.pdf : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
Last accessed 12 February 2014

6. Hefti, M.M. et al. Severity of Inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum. 2009 February; 52(2): 193–197.

" title="http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140221005640r1&sid=16929&distro=ftp\"/>" target="_blank" rel="nofollow">cts.businesswire.com/ct/CT?id=bwnews&sty=20140221005640r1&am ..

F Suleyman (MSD)01992 455389 funda.suleyman@merck.com : mailto:funda.suleyman@merck.com orYasmin

Ghariani (Pegasus)01903 821550 yghariani@thisispegasus.co.uk : mailto:yghariani@thisispegasus.co.uk


Author:
Hossam Abdel-Kader
e-mail
Web: www.pr-inside.com/
Phone: +43 1 9582319

Disclaimer: (c) 2014 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com